Valuation: Theralase Technologies Inc.

Market Cap 75.4M 53.82M 47.03M 43.4M 40M 5.18B 77.07M 519M 204M 2.54B 202M 198M 8.74B P/E 2026 *
-25.5x
P/E 2027 * 12.8x
Enterprise Value 75.4M 53.82M 47.03M 43.4M 40M 5.18B 77.07M 519M 204M 2.54B 202M 198M 8.74B EV / Sales 2026 *
94x
EV / Sales 2027 * 2.22x
Free-Float
87.46%
Yield 2026 *
-
Yield 2027 * -
1 week-1.92%
1 month+8.51%
3 months-17.74%
6 months-3.77%
Current year+54.55%
1 week 0.25
Extreme 0.25
0.27
1 month 0.22
Extreme 0.225
0.28
Current year 0.16
Extreme 0.16
0.41
1 year 0.14
Extreme 0.145
0.41
3 years 0.14
Extreme 0.14
0.41
5 years 0.14
Extreme 0.14
0.48
10 years 0.12
Extreme 0.12
0.6
Manager TitleAgeSince
Chief Executive Officer - 29/06/2023
Director of Finance/CFO - 27/06/2019
Chief Executive Officer - 15/11/2021
Director TitleAgeSince
Chairman - -
Director/Board Member - 01/01/2008
Director/Board Member - 27/06/2019
Date Insider Type Main position Quantity % Market Cap.
21/05/26 Buy

Director

20,900 0.0081%
20/05/26 Sell

Chief Executive Officer

25,000 0.0097%
20/05/26 Option

Chief Technology Officer

11,000 0.0043%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-1.92%+24.39%-13.56% 53.82M
-0.73%-2.23%+39.40%+52.20% 1.5B
0.00%-6.96%-47.81%-51.03% 267M
-0.92%-2.27%-11.74%-51.69% 52.75M
Average -0.41%-2.86%+1.06%-16.02% 468.39M
Weighted average by Cap. -0.61%-1.03%+25.12%+32.70%

Financials

2026 *2027 *
Net sales 802K 572K 500K 462K 426K 55.13M 820K 5.52M 2.17M 27M 2.15M 2.1M 92.94M 33.89M 24.19M 21.14M 19.51M 17.98M 2.33B 34.64M 233M 91.7M 1.14B 90.84M 88.85M 3.93B
Net income -4.2M -3M -2.62M -2.42M -2.23M -289M -4.29M -28.9M -11.37M -141M -11.26M -11.01M -487M 6.83M 4.88M 4.26M 3.93M 3.62M 470M 6.98M 47M 18.48M 230M 18.31M 17.91M 792M
Net Debt - -
Logo Theralase Technologies Inc.
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.
Employees
20
Date Price Change Volume
17/07/26 CA$0.2550 0.00% 52,269
16/07/26 CA$0.2550 0.00% 65,964
15/07/26 CA$0.2550 -3.77% 18,002
14/07/26 CA$0.2650 +1.92% 5,152
13/07/26 CA$0.2600 0.00% 132,190
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.2550CAD
Average target price
0.7000CAD
Spread / Average Target
+174.51%

Quarterly revenue - Rate of surprise